| SC 13D/A | 2024-04-12 | ORBIMED ADVISORS LLC | Passage BIO, Inc. | 8,034,000 | 13.0% | EDGAR |
| SC 13G | 2024-03-29 | Lynx1 Capital Management LP | Passage BIO, Inc. | 4,845,871 | 8.7% | EDGAR |
| SC 13G/A | 2024-02-14 | Lynx1 Capital Management LP | Passage BIO, Inc. | 379,159 | 0.7% | EDGAR |
| SC 13D/A | 2023-11-09 | Versant Venture Capital VI, L.P. | Passage BIO, Inc. | 4,026,417 | 7.3% | EDGAR |
| SC 13D/A | 2023-06-29 | ORBIMED ADVISORS LLC | Passage BIO, Inc. | 8,034,000 | 14.7% | EDGAR |
| SC 13D/A | 2023-06-15 | Frazier Life Sciences IX, L.P. | Passage BIO, Inc. | 2,543,698 | 4.7% | EDGAR |
| SC 13G/A | 2023-02-14 | Lynx1 Capital Management LP | Passage BIO, Inc. | 3,355,917 | 5.1% | EDGAR |
| SC 13G/A | 2023-02-14 | Deep Track Capital, LP | Passage BIO, Inc. | 0 | 0.0% | EDGAR |
| SC 13G | 2022-09-29 | Lynx1 Capital Management LP | Passage BIO, Inc. | 2,752,422 | 5.1% | EDGAR |
| SC 13D/A | 2022-08-15 | Frazier Life Sciences IX, L.P. | Passage BIO, Inc. | 3,756,915 | 6.9% | EDGAR |
| SC 13G | 2022-07-08 | BlackRock Inc. | Passage BIO, Inc. | 1,368,347 | 2.5% | EDGAR |
| SC 13D/A | 2022-05-05 | ORBIMED ADVISORS LLC | Passage BIO, Inc. | 6,841,423 | 12.6% | EDGAR |
| SC 13G/A | 2022-02-14 | Deep Track Capital, LP | Passage BIO, Inc. | 3,216,997 | 6.0% | EDGAR |
| SC 13G/A | 2022-02-14 | Access Industries Holdings LLC | Passage BIO, Inc. | 2,616,630 | 4.8% | EDGAR |
| SC 13G/A | 2022-02-09 | LAV Prescience Ltd | Passage BIO, Inc. | 2,199,676 | 4.1% | EDGAR |
| SC 13G | 2022-02-04 | BlackRock Inc. | Passage BIO, Inc. | 3,491,555 | 6.5% | EDGAR |
| SC 13G/A | 2021-12-10 | FMR LLC | Passage BIO, Inc. | 2,667,917 | 4.9% | EDGAR |
| SC 13G | 2021-10-25 | Deep Track Capital, LP | Passage BIO, Inc. | 2,852,940 | 5.3% | EDGAR |
| SC 13G/A | 2021-02-12 | Vivo Capital VIII, LLC | Passage BIO, Inc. | 1,487,038 | 2.8% | EDGAR |
| SC 13G | 2021-02-11 | New Leaf Ventures III, L.P. | Passage BIO, Inc. | 2,497,922 | 4.7% | EDGAR |